Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 7795-7797 [2013-02310]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 23 / Monday, February 4, 2013 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: January 29, 2013.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–02271 Filed 2–1–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Review of a resource grant application in rat
embryonic stem cell lines.
Date: February 21, 2013.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7206, Bethesda, MD
20892, (Telephone Conference Call).
Contact Person: Shelley S Sehnert, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7206, Bethesda, MD 20892–7924, 301–435–
0303, ssehnert@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
VerDate Mar<15>2010
19:26 Feb 01, 2013
Jkt 229001
Dated: January 29, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–02277 Filed 2–1–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Fogarty International Center; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Fogarty
International Center Advisory Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract Proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable materials, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Fogarty International
Center Advisory Board.
Date: February 25–26, 2013.
Closed: February 25, 2013, 2:00 p.m. to
5:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Building 31, 31 Center Drive, C Wing, Room
B2C03, Bethesda, MD 20892.
Open: February 26, 2013 9:00 a.m. to 3:00
p.m.
Agenda: Discussions will focus on new
directions for Fogarty International Center
non-communicable diseases portfolio and
strengthening collaborations between
researchers and implementers and
policymakers.
Place: National Institutes of Health,
Lawton L. Chiles International House,
Bethesda, MD 20892.
Contact Person: Robert Eiss, Public Health
Advisor, Fogarty International Center,
National Institutes of Health, 31 Center Drive,
Room B2c02, Bethesda, MD 20892, (301)
496–1415, EISSR@MAIL.NIH.GOV.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
7795
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: www.nih.gov/
fic/about/advisory.html, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.106, Minority International
Research Training Grant in the Biomedical
and Behavioral Sciences; 93.154, Special
International Postdoctoral Research Program
in Acquired Immunodeficiency Syndrome;
93.168, International Cooperative
Biodiversity Groups Program; 93.934, Fogarty
International Research Collaboration Award;
93.989, Senior International Fellowship
Awards Program, National Institutes of
Health HHS)
Dated: January 29, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–02282 Filed 2–1–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
SUMMARY:
E:\FR\FM\04FEN1.SGM
04FEN1
7796
Federal Register / Vol. 78, No. 23 / Monday, February 4, 2013 / Notices
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in
the Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
Mrs.
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs’’, as amended in the
revisions listed above, requires strict
standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.
To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
mstockstill on DSK4VPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Mar<15>2010
19:26 Feb 01, 2013
Jkt 229001
and specimen validity tests on urine
specimens:
Instrumented Initial Testing Facilities
(IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–877–7016, (Formerly:
Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264
Advanced Toxicology Network, 3560
Air Center Cove, Suite 101, Memphis,
TN 38118, 901–794–5770/888–290–
1150
Aegis Analytical Laboratories, 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917
Doctors Laboratory, Inc., 2906 Julia
Drive, Valdosta, GA 31602, 229–671–
2281
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
Fortes Laboratories, Inc., 25749 SW.
Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503–486–1023
Gamma-Dynacare Medical
Laboratories*, A Division of the
Gamma-Dynacare Laboratory
Partnership, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919–
572–6900/800–833–3984, (Formerly:
LabCorp Occupational Testing Services,
Inc., CompuChem Laboratories, Inc.;
CompuChem Laboratories, Inc., A
Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem
Laboratories, Inc., A Member of the
Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street, Southaven,
MS 38671, 866–827–8042/800–233–
6339, (Formerly: LabCorp Occupational
Testing Services, Inc.; MedExpress/
National Laboratory Center)
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS 66219,
913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.,)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR 97232,
503–413–5295/800–950–5295
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology Laboratory,
1 Veterans Drive, Minneapolis, MN
55417, 612–725–2088
National Toxicology Laboratories,
Inc., 1100 California Ave., Bakersfield,
CA 93304, 661–322–4250/800–350–
3515
One Source Toxicology Laboratory,
Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888–747–3774, (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942, (Formerly: Centinela
Hospital Airport Toxicology Laboratory)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7
Phamatech, Inc., 10151 Barnes
Canyon Road, San Diego, CA 92121,
858–643–5555
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
800–729–6432, (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
E:\FR\FM\04FEN1.SGM
04FEN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 23 / Monday, February 4, 2013 / Notices
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304,
818–737–6370, (Formerly: SmithKline
Beecham Clinical Laboratories)
Redwood Toxicology Laboratory,
3650 Westwind Blvd., Santa Rosa, CA
95403, 707–570–4434
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend, IN
46601, 574–234–4176 x1276
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040, 602–438–8507/800–279–
0027
STERLING Reference Laboratories, 2617
East L Street, Tacoma, Washington
98421, 800–442–0438
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203, 573–882–1273
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085
*The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 30, 2010 (75 FR
22809). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program.
Janine Denis Cook,
Chemist, Division of Workplace Programs,
Center for Substance Abuse Prevention,
SAMHSA.
[FR Doc. 2013–02310 Filed 2–1–13; 8:45 am]
BILLING CODE 4160–20–P
VerDate Mar<15>2010
19:26 Feb 01, 2013
Jkt 229001
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2013–0005]
Homeland Security Information
Network Advisory Committee
(HSINAC)
OPS/OCIO, DHS.
Committee Management; Notice
of Federal Advisory Committee Meeting.
AGENCY:
ACTION:
The Homeland Security
Information Network Advisory
Committee (HSIN AC) will meet on
February 27th–28th, 2013 in
Washington, DC. The meeting will be
open to the public.
DATES: HSIN AC will meet Wednesday,
February 27th, 2013 from 9 a.m. to 5
p.m. and on Thursday, February 28th,
2013 from 9 a.m. to 2 p.m. Please note
that the meeting may end early if the
committee has completed its business.
ADDRESSES: The meeting will be held at
the Ronald Reagan International Trade
Center (Ronald Reagan Building), 1300
Pennsylvania Ave. NW., Washington DC
20004. All visitors to the Ronald Reagan
International Trade Center are required
to show government identification for
admittance to the building. In the event
of inclement weather affecting the
Washington, DC area, creating a delay in
the opening of Federal offices, the
contingency plan will be to hold the
conference via a teleconference call and
if possible Adobe Connect session,
requesting that all participants and
visitors participate virtually. If the
Federal government is closed, the
meeting will be rescheduled. Please
provide your name, telephone number
and email by close of business on
February 25th, 2013, to the contact
person listed in FOR FURTHER
INFORMATION CONTACT below.
Teleconference lines will be available
for this meeting.
For information on facilities or
services for individuals with disabilities
or to request special assistance at the
meeting, contact David Steigman,
david.steigman@hq.dhs.gov, 202–357–
7809, as soon as possible.
To facilitate public participation, we
are inviting public comment on the
issues to be considered by the
committee as listed in the ‘‘Agenda’’
section below. Comments must be
submitted in writing no later than
February 20, 2013 and must be
identified by docket number: DHS–
2013–0005 and may be submitted by
one of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
SUMMARY:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
7797
• Email: David Steigman,
david.steigman@hq.dhs.gov. Include the
docket number in the subject line of the
message.
• Fax: 202–357–7678.
• Mail: David Steigman, Department
of Homeland Security, OPS CIO–D Stop
0426, 245 Murray Lane, SW., BLDG 410,
Washington, DC 20528–0426.
Instructions: All submissions received
must include the words ‘‘Department of
Homeland Security’’ and the docket
number for this action. Comments
received will be posted without
alteration at https://www.regulations.gov,
including any personal information
provided.
Docket: For access to the docket to
read background documents or
comments received by the (Homeland
Security Information Network Advisory
Committee), go to https://
www.regulations.gov.
Short public comment periods will be
held during the meeting following
presentations. Those providing
comments are requested to limit their
comments to 3 minutes. Please note that
the public comment period may end
before the time indicated, following the
last call for comments. Contact the
individual listed below to register as a
speaker. Documents will be distributed
to the committee members during the
meeting and made available to the
public on February 27, 2013 on the
Federal Register Web site at: https://
www.federalregister.gov/agencies/
homeland-security-department. These
documents will be formatted in the
Microsoft Suite software applications.
FOR FURTHER INFORMATION CONTACT:
Designated Federal Officer, David
Steigman, david.steigman@hq.dhs.gov,
Phone: 202–357–7809, Fax: 202–357–
7678, or Alternate Designated Federal
Officer, Sarah Schwettman,
sarah.schwettman@hq.dhs.gov, Phone:
202–357–7882.
SUPPLEMENTARY INFORMATION: Notice of
this meeting is given under the Federal
Advisory Committee Act, 5 U.S.C. App.
(Pub. L. 92–463).
The HSINAC provides advice and
recommendations to the U.S.
Department of Homeland Security
(DHS) on matters relating to HSIN.
These matters include system
requirements, operating policies,
community organization, knowledge
management, interoperability and
federation with other systems, and any
other aspect of HSIN that supports the
operations of DHS and its Federal, State,
territorial, local, tribal, international,
and private sector mission partners. The
HSINAC provides independent advice
and recommendations to the leadership
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 78, Number 23 (Monday, February 4, 2013)]
[Notices]
[Pages 7795-7797]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-02310]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories and Instrumented Initial Testing
Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing
for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the Laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory Guidelines were first published
in the Federal Register on April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal Register on June 9, 1994 (59 FR
29908); September 30, 1997 (62 FR 51118);
[[Page 7796]]
April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December
10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809).
A notice listing all currently certified Laboratories and
Instrumented Initial Testing Facilities (IITF) is published in the
Federal Register during the first week of each month. If any
Laboratory/IITF's certification is suspended or revoked, the
Laboratory/IITF will be omitted from subsequent lists until such time
as it is restored to full certification under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially
developed in accordance with Executive Order 12564 and section 503 of
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace
Drug Testing Programs'', as amended in the revisions listed above,
requires strict standards that Laboratories and Instrumented Initial
Testing Facilities (IITF) must meet in order to conduct drug and
specimen validity tests on urine specimens for Federal agencies.
To become certified, an applicant Laboratory/IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a Laboratory/IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and Instrumented Initial Testing Facilities (IITF) in
the applicant stage of certification are not to be considered as
meeting the minimum requirements described in the HHS Mandatory
Guidelines. A Laboratory/IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory Guidelines dated November 25, 2008
(73 FR 71858), the following Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the minimum standards to conduct drug
and specimen validity tests on urine specimens:
Instrumented Initial Testing Facilities (IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-
7840/800-877-7016, (Formerly: Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624,
585-429-2264
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis,
TN 38118, 901-794-5770/888-290-1150
Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210, 615-
255-2400, (Formerly: Aegis Sciences Corporation, Aegis Analytical
Laboratories, Inc.)
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock,
AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology Laboratory
Baptist Medical Center)
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 800-
445-6917
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609
Fortes Laboratories, Inc., 25749 SW. Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503-486-1023
Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare
Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A
1P4, 519-679-1630
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa,
KS 66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.,)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN
55112, 651-636-7466/800-832-3244
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff,
Pasadena, TX 77504, 888-747-3774, (Formerly: University of Texas
Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology
Laboratory)
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509-755-8991/800-541-7891x7
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121,
858-643-5555
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA
30084, 800-729-6432, (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA
19403, 610-631-4600/877-642-2216, (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories)
[[Page 7797]]
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA
91304, 818-737-6370, (Formerly: SmithKline Beecham Clinical
Laboratories)
Redwood Toxicology Laboratory, 3650 Westwind Blvd., Santa Rosa, CA
95403, 707-570-4434
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601, 574-234-4176 x1276
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507/800-279-0027
STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington
98421, 800-442-0438
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO
65203, 573-882-1273
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085
*The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on April 30, 2010 (75 FR 22809).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Janine Denis Cook,
Chemist, Division of Workplace Programs, Center for Substance Abuse
Prevention, SAMHSA.
[FR Doc. 2013-02310 Filed 2-1-13; 8:45 am]
BILLING CODE 4160-20-P
